right with good will and Cedric, everyone. morning, I in jump SYFOVRE. Thanks,
both recently, early an and the have Initially, past we've by adopters. base As success SYFOVRE driven seen over our strong. Cedric prescriber driving been sales. demand increasing uptake was patient largely sales XX shared, More new months fast from
to getting provider focus also eye are network patients the on our the efforts with specialists, we educating continue referring marketing of care the we need. retina they While importance on treatment GA
we patient distributed quarter, samples. investing XX,XXX first our are Suffice SYFOVRE efforts direct-to-consumer commercial education X,XXX off. In we say and doses to initiatives in GA. increase and marketing Further, paying and about to awareness the that are
largest were March, demand in monthly The resulting first varied of through this biggest February and QX. the the X since date as in January and some month launched then months rates to quarter. decline Growth a the slight weeks our of largest compared X reacceleration months a in of with to volume year
QX, come board we see of range double-digit types. to in of sites each With using continue new on a X,XXX over sites week. across broad Additionally, of a number now SYFOVRE care practice
as has be back continued both to And incredible are by growth across in have second now an sharing patients. the launch. will year, you quarter quarter that end. metrics key been far its we the We going and thrilled seen in we new It we existing are so of second with
approximately first the at injections. What X,XXX. the Regarding we in be estimated remains about X X this in injection following rare a to that first XX,XXX learned have rate at injection with rate our phenomenon is vasculitis, appears
seeing Given stable, the are are real-world and in rates or patients. we start these had or rare SYFOVRE experience their physicians more extensive now either SYFOVRE confident more of use to with and use it decreased paused use that who retina date, specialists many again are their
GA Shifting to the gears market. longer-term #X approximately for the remains treated chosen with dynamics. of XX% SYFOVRE treatment
the patients ECP. recent to and we The GA United due stages prevalence estimated only of States. remain confident safety of it XX% are flexible profile, only more, a are up early the managed X.X will analysis, large our efficacy, in set. strong by robustness Even well-documented up claims on We the by and are make market estimated are in Today, million to market is an of the have growing leader its market. based has of data a those dosing diagnosed patients overall that treated the who defined patients to been and
diagnosed many patients However, been have are GA a or referred not specialist. not yet to
patients a In been a treated there SYFOVRE patients This not huge continues to only for GA as vast of currently with majority referrals. means newly are have fact, small yet opportunity SYFOVRE treated. being of portion the diagnosed be
we Now never the next that executing year a strategy. commercial available. transformative had treatment in a X, our that medicine are disease a stage of has Remember, we we for launching are are
So lot physicians drives we have patients. what a and learned about both
targets reach physicians. expand well those have within with existing SYFOVRE start physician amongst me further to use increase who We used not as plan yet. our as Let our
retinal better summer. messaging then is our last messaging our as [ launch, At refining safety ] are focused to shifted efficacy, We we on change. initially understand what
the OAKS and our have functional to benefits post with from we back pivoted to study multiple hoc demonstrate data the leading highlighting results our positive and X-year efficacy, Now DERBY addition GALE following treatment. in that analyses SYFOVRE extension
care also to broadening are providers who education other disease reach patients. of of eye referring tens GA see thousands state We to provide our
leader, right of the on doctors see and treatment who can are treatment As market specialist the that educating GA those patients then decide the we a approach. importance
patients. Moving to
treatment their motivated are decisions. past the over actively learning patients key year how in engaged and is Another
As new We a of initial seen These number patients on positive was thousands netted awareness focus GA diagnosis now and on treatment encouraging efforts our with results, you professional. GA SYFOVRE. very message to branded patients may about launched care focused DTC of their physicians starting to GA treatment. have the unbranded see patients SYFOVRE including recently of to significant and our DTC with in have campaign a talk encouraging increasing their eye campaign,
this for treatment the and accelerate is awareness, GA. and campaign to more patients goal speed increase Our to diagnosis many of access
safety product incredibly patient are of PNH. $XX still very me quarter With rates over heightened exposure, have to in remain Now of rates for to systemic a and low XX%, years compelling let continues But the of meningococcal profile. obviously, been thrombosis. now seeing also zero the were have X,XXX infection Revenues there competition. pegcetacoplan and Compliance cases we EMPAVELI shift million. at high
we X months. the least on sales the market, entrant EMPAVELI With new next at XX for in the pressure to anticipate
and EMPAVELI be we oral. to physicians medium is is realistic the flat treatment to team expect new an still that expect X-year its a data real-world patients The see starting want expected to profile switching strong profile. focused to be I foothold, on Although some EMPAVELI demand in see the to of also emphasizing but strong term. with including We we have safety efficacy on patients laser
return and will over We time. this are that to confident profile patients some EMPAVELI drive physicians to
very early, few this. While we've seen of a instances still already
Finally, opportunity patient primary a with expand infrastructure detail need population utilization to particularly teams have such EMPAVELI unmet we potentially into and excited our we that leverage we diseases. CXG on are to Xx and nephrologists about are the patients to than tremendous as of will Caroline? will bigger These existing give of the able approved, EMPAVELI is physicians. devastating reach Caroline If field-based our X and to for PNH. diseases and these be deliver opportunity much IC-MPGN. more
